Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DL2HO7
|
|||
| Drug Name |
F-652
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Graft-versus-host disease [ICD-11: 4B24; ICD-9: 279.5] | Phase 2 | [1] | |
| Company |
Evive Biotech Bridgewater, NJ
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-22 (IL22) | Target Info | Agonist | [2] |
| NetPath Pathway | IL9 Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02406651) A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT). U.S.National Institutes of Health. | |||
| REF 2 | An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. Hepatology. 2020 Aug;72(2):441-453. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.